Aktis Oncology, Inc. (AKTS) company profile
Close on Nov 17, 2026Market cap $907.15MP/E –Yield –
About Aktis Oncology
Pharmaceutical Preparations, SIC 2834
Aktis Oncology, Inc. is a clinical-stage biopharmaceutical company that develops targeted radiopharmaceuticals to treat solid tumors. The company utilizes a proprietary miniprotein radioconjugate platform to bind radioisotope payloads, such as alpha-emitting actinium-225, to cancer cells while rapidly clearing normal tissues. Its lead product candidate, [225Ac]Ac-AKY-1189, targets Nectin-4-expressing cancers, including urothelial cancer and other solid tumors such as lung, breast, colorectal, and cervical malignancies. Another candidate in development, [225Ac]Ac-AKY-2519, targets B7-H3-expressing tumors such as prostate and lung cancers. The company also maintains early-stage discovery programs and a research collaboration with Eli Lilly. Its target patients are individuals diagnosed with solid tumor cancers expressing these specific tumor markers.
The company is based in the United States, with corporate headquarters located in Boston, Massachusetts. Its operations include a multi-site clinical trial network across the United States, along with research and development facilities. Aktis Oncology works with domestic and international suppliers and contract manufacturers for isotope sourcing and drug manufacturing.
Summary of the business section of Aktis Oncology's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Aktis Oncology, Inc.
- Headquarters
- Boston, MA
- Address
- 17 Drydock Avenue, Suite #17-401 02210
- Phone
- (978) 237-4380
- Website
- aktisoncology.com
- Employees
- 79, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- AKTS
- Exchange
- Nasdaq
- IPO date
- Jan 9, 2026
- Shares outstanding
- 56M, Jul 31, 2026
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 2035832
- CUSIP
- 01021M104
- ISIN
- US01021M1045
- FIGI
- BBG00ZQS8KZ1
- Share class FIGI
- BBG00ZQS8L07
- EIN
- 85-2584233
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Matthew Roden | President and CEO, Director | 91,998 |
| Akos Czibere | Chief Medical Officer | 0 |
| Shulamit Ron-Bigger | Chief Operating Officer | 34,200 |
| Paul L. Feldman | Chief Scientific Officer | 144,568 |
| Kyle D. Kuvalanka | Chief Financial Officer | – |
| Ken Herrmann | Director | 3,506 |
| Glenn Gormley | Director | – |
| Todd Foley | Director | 4,002,533 |
| Helen Susan Kim | Director | 5,671,825 |
| Oleg Nodelman | Director | 433,527 |
| EcoR1 Capital, LLC | Director | – |
| Lloyd Mitchell Segal | Director | 19,631 |
| Michael A. Sherman | Director | – |
| Mary Thistle | Director | – |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jan 9, 2026
- Offer price
- $18.00
- Securities offered
- 17,650,000
- Gross proceeds
- $317.70M
- Exchange
- Nasdaq
- Lock-up ends (est.)
- Jul 8, 2026
“Per share Total Initial public offering price $ 18.00 $ 317,700,000 Underwriting discounts and commissions (1) $ 1.26 $ 22,239,000 Proceeds before expenses, to Aktis Oncology, Inc.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 9, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 7, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?